Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009:3:143.
doi: 10.3332/ecancer.2009.143. Epub 2009 May 12.

Intraprostatic fiducial markers: a potential application for ultrasound-guided radiotherapy in prostate cancer

A Vavassori  1 , Ba Jereczek-Fossa, D Zerini, L De Cicco, R Cambria, F Cattani, C Garibaldi, M Ciocca, R Orecchia
Affiliations

Intraprostatic fiducial markers: a potential application for ultrasound-guided radiotherapy in prostate cancer

A Vavassori et al. Ecancermedicalscience. 2009.

Abstract

We report on a two-phase test performed to assess the ability of the ultrasound-based B-mode acquisition and targeting (BAT) trans-abdominal system to identify non-dedicated fiducial markers implanted into the prostate gland for subsequent image-guided radiotherapy.Although further investigation is warranted in order to identify the optimal echogenic marker and to define its potential use for image-guided radiotherapy in prostate cancer patients, we demonstrate the feasibility of the BAT system for the visualization of non-ultrasound-dedicated markers.

PubMed Disclaimer

Figures

Figure 1:
Figure 1:
US-images and simulation-CT contours of the bladder, prostate and rectum in the IGRT patient with VisiCoil markers implanted (white arrows).
Figure 2:
Figure 2:
US and x-ray images of the CyberMark™ markers (dotted circles) in the brachytherapy patient.
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Pollack A, Zagars GK, Starkschall G, et al. Prostate cancer radiation dose response: results of the MD Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys. 2002;53:1097–105. doi: 10.1016/S0360-3016(02)02829-8. - DOI - PubMed
    1. Hanks GE, Hanlon AL, Epstein B, Horwitz EM. Dose response in prostate cancer with 8–12 years’ follow-up. Int J Radiat Oncol Biol Phys. 2002;54:427–35. - PubMed
    1. Kupelian P, Kuban D, Thames H, et al. Improved biochemical relapse-free survival with increased external radiation doses in patients with localized prostate cancer: the combined experience of nine institutions in patients treated in 1994 and 1995. Int J Radiat Oncol Biol Phys. 2005;61:415–9. - PubMed
    1. Peeters ST, Heemsbergen WD, Koper PC, et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006;24:1990–6. doi: 10.1200/JCO.2005.05.2530. - DOI - PubMed
    1. Kuban DA, Tucker SL, Dong L, et al. Long-term results of the MD Anderson randomized dose-escalation trial for prostate cancer. Int J Radiat Oncol Biol Phys. 2008;70:67–74. - PubMed

LinkOut - more resources